{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:35:16Z","timestamp":1791891316635,"version":"4.3.4"},"reference-count":419,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1378\/chest.08-0670","type":"journal-article","created":{"date-parts":[[2008,6,23]],"date-time":"2008-06-23T19:37:53Z","timestamp":1214249873000},"page":"160S-198S","source":"Crossref","is-referenced-by-count":1702,"special_numbering":"S","title":["Pharmacology and Management of the Vitamin K Antagonists"],"prefix":"10.1016","volume":"133","author":[{"given":"Jack","family":"Ansell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Hylek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gualtiero","family":"Palareti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1378\/chest.08-0670_bib1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/bi00601a003","article-title":"Mechanisms of coumarin action: significance of vitamin K epoxide reductase inhibition","volume":"17","author":"Whitlon","year":"1978","journal-title":"Biochemistry"},{"key":"10.1378\/chest.08-0670_bib2","doi-asserted-by":"crossref","first-page":"11210","DOI":"10.1016\/S0021-9258(18)33742-6","article-title":"Evidence that warfarin anticoagulant action involves two distinct reductase activities","volume":"257","author":"Fasco","year":"1982","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0670_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1988.tb03274.x","article-title":"The relationship between inhibition of vitamin K 1,2,3-epoxide reductase and reduction of clotting factor activity with warfarin","volume":"25","author":"Choonara","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.08-0670_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0003-9861(88)90571-1","article-title":"Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3 epoxide: evidence for multiple pathways of hydroxyvitamin K formation","volume":"264","author":"Trivedi","year":"1988","journal-title":"Arch Biochem Biophys"},{"key":"10.1378\/chest.08-0670_bib5","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1073\/pnas.71.7.2730","article-title":"Vitamin K dependent modifications of glutamic acid residues in prothrombin","volume":"71","author":"Stenflo","year":"1974","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1378\/chest.08-0670_bib6","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1016\/S0021-9258(19)42259-X","article-title":"The mode of action of vitamin K: identification of gamma-carboxyglutamic acid as a component of prothrombin","volume":"249","author":"Nelsestuen","year":"1974","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0670_bib7","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1111\/j.1538-7836.2005.01419.x","article-title":"The vitamin K cycle","volume":"3","author":"Stafford","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0005-2795(77)90155-6","article-title":"A spectrum of partially carboxylated prothrombins in the plasmas of coumarin treated patients","volume":"494","author":"Friedman","year":"1977","journal-title":"Biochim Biophys Acta"},{"key":"10.1378\/chest.08-0670_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0021-9258(18)89728-9","article-title":"The kinetics of activation of normal and gamma carboxy-glutamic acid deficient prothrombins","volume":"260","author":"Malhotra","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0670_bib10","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1016\/S0021-9258(17)33107-1","article-title":"Role of gamma-carboxyglutamic acid: an unusual transition required for calcium-dependent binding of prothrombin to phospholipid","volume":"251","author":"Nelsestuen","year":"1976","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0670_bib11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S0021-9258(19)75174-6","article-title":"Differentiation of metal ion-induced transitions of prothrombin fragment 1","volume":"252","author":"Prendergast","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0670_bib12","doi-asserted-by":"crossref","first-page":"14969","DOI":"10.1016\/S0021-9258(18)66814-0","article-title":"Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid","volume":"261","author":"Borowski","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0670_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11239-005-2473-4","article-title":"The importance of factor Xa regulatory pathways in vascular thromboresistance: focus on protein Z","volume":"19","author":"Becker","year":"2005","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib14","first-page":"990","article-title":"Osteocalcin and matrix Gla protein: vitamin K dependent proteins in bone","volume":"69","author":"Hauschka","year":"1989","journal-title":"Phys Rev"},{"key":"10.1378\/chest.08-0670_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.nu.08.070188.003025","article-title":"Role of vitamin K-dependent proteins in bone metabolism","volume":"8","author":"Price","year":"1988","journal-title":"Annu Rev Nutr"},{"key":"10.1378\/chest.08-0670_bib16","first-page":"1599","article-title":"Protein S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts","volume":"130","author":"Maillard","year":"1997","journal-title":"Endocrinology"},{"key":"10.1378\/chest.08-0670_bib17","doi-asserted-by":"crossref","first-page":"13398","DOI":"10.1016\/S0021-9258(17)38734-3","article-title":"Sequence of the precursor to rat bone Y-carboxyglutamic acid protein that accumulated in warfarin-treated osteosarcoma cells","volume":"260","author":"Pan","year":"1985","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0670_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0022-3476(75)80986-3","article-title":"Congenital malformations associated with the administration of oral anticoagulants during pregnancy","volume":"86","author":"Pettifor","year":"1975","journal-title":"J Pediatr"},{"key":"10.1378\/chest.08-0670_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0002-9343(80)90181-3","article-title":"Maternal and fetal sequelae of anticoagulation during pregnancy","volume":"68","author":"Hall","year":"1980","journal-title":"Am J Med"},{"key":"10.1378\/chest.08-0670_bib20","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1203\/01.PDR.0000155943.07244.04","article-title":"Reduced bone density in children on long-tern warfarin","volume":"57","author":"Barnes","year":"2005","journal-title":"Pediatr Res"},{"key":"10.1378\/chest.08-0670_bib21","first-page":"19","article-title":"Oral anticoagulant drugs: pharmacokinetic aspects","volume":"15","author":"Breckenridge","year":"1978","journal-title":"Semin Hematol"},{"key":"10.1378\/chest.08-0670_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev.me.27.020176.001333","article-title":"Vitamin K and other oral anticoagulant drugs","volume":"27","author":"O'Reilly","year":"1976","journal-title":"Annu Rev Med"},{"key":"10.1378\/chest.08-0670_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-197904010-00001","article-title":"Clinical pharmacokinetics of oral anticoagulants","volume":"4","author":"Kelly","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"10.1378\/chest.08-0670_bib24","series-title":"The new dimensions of warfarin prophylaxis: advances in experimental medicine and biology","first-page":"205","article-title":"Warfarin metabolism and drug-drug interactions","author":"O'Reilly","year":"1986"},{"key":"10.1378\/chest.08-0670_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.08-0670_bib26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2125.1981.tb01280.x","article-title":"Pharmacokinetics of the enantiomers of acenocoumarol in man","volume":"12","author":"Godbillon","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.08-0670_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-2007-996417","article-title":"Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon","volume":"25","author":"Huastein","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.08-0670_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15563650600795487","article-title":"Long-acting anticoagulant rodenticide poisoning: an evidence-based consensus guideline for out-of-hospital management","volume":"45","author":"Caravati","year":"2007","journal-title":"Clin Toxicol"},{"key":"10.1378\/chest.08-0670_bib29","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1001\/archinte.1993.00410160099010","article-title":"Case management and plasma half-life in a case of brodifacoum poisoning","volume":"153","author":"Hollinger","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/01.mbc.0000169215.70184.56","article-title":"Successful reversal of anticoagulant effect of superwarfarin poisoning with recombinant activated factor VII","volume":"16","author":"Zupancic-Salek","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.08-0670_bib31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00003088-200140080-00003","article-title":"Pharmacogenetics of warfarin elimination and its clinical implications","volume":"40","author":"Takahashi","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1378\/chest.08-0670_bib32","first-page":"29:1","article-title":"Pharmacology of warfarin and related anticoagulants","volume":"1","author":"Wittkowsky","year":"2003","journal-title":"Managing oral anticoagulation therapy: clinical and operational guidelines"},{"key":"10.1378\/chest.08-0670_bib33","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0140-6736(98)00326-2","article-title":"Genetic control of anticoagulation","volume":"353","author":"Mannucci","year":"1999","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clpt.2005.01.019","article-title":"CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes","volume":"77","author":"Veenstra","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0670_bib35","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1160\/TH05-10-0678","article-title":"The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement","volume":"95","author":"Herman","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1067\/mcp.2001.117444","article-title":"Individual variability in sensitivity to warfarin: nature or nurture","volume":"70","author":"Loebstein","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0670_bib37","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib38","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Influence of CYP2C9 genetic variants on the risk of over anticoagulation and of bleeding events during warfarin therapy","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0670_bib39","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cca.2005.11.026","article-title":"CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese","volume":"367","author":"Chern","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1378\/chest.08-0670_bib40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-0037-1612583","article-title":"A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) in a patient on warfarin therapy","volume":"95","author":"Herman","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1160\/TH03-12-0741","article-title":"The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon","volume":"92","author":"Visser","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib42","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.clpt.2004.01.007","article-title":"CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences","volume":"75","author":"Takahashi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0670_bib43","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0006-2952(74)90002-1","article-title":"Biochemical basis of hereditary resistance to warfarin in the rat","volume":"23","author":"Zimmerman","year":"1974","journal-title":"Biochem Pharmacol"},{"key":"10.1378\/chest.08-0670_bib44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature02214","article-title":"Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2","volume":"427","author":"Rost","year":"2004","journal-title":"Nature"},{"key":"10.1378\/chest.08-0670_bib45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature02254","article-title":"Identification of the gene for vitamin K epoxide reductase","volume":"427","author":"Li","year":"2004","journal-title":"Nature"},{"key":"10.1378\/chest.08-0670_bib46","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2004-06-2111","article-title":"A polymorphism in the VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin","volume":"105","author":"D'Andrea","year":"2005","journal-title":"Blood"},{"key":"10.1378\/chest.08-0670_bib47","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","volume":"352","author":"Rieder","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib48","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1160\/TH05-04-0290","article-title":"VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation","volume":"94","author":"Geisen","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib49","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","article-title":"The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen","volume":"106","author":"Sconce","year":"2005","journal-title":"Blood"},{"key":"10.1378\/chest.08-0670_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1160\/TH04-08-0540","article-title":"Pharmacodynamic resistance to warfarin associated with Val66Met substitution in vitamin K epoxide reductase complex subunit 1","volume":"93","author":"Harrington","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1538-7836.2006.01759.x","article-title":"Population variation in VKORC1 haplotype structure","volume":"4","author":"Marsh","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1046\/j.1365-2141.1997.2213036.x","article-title":"Missence mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy","volume":"98","author":"Oldenburg","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.08-0670_bib53","first-page":"1","article-title":"Therapeutic management of a patient with a unique factor IX sensitivity to warfarin","volume":"4","author":"Scialla","year":"2005","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1378\/chest.08-0670_bib54","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib55","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM197612232952613","article-title":"Enantiomers of warfarin and phenobarbital","volume":"295","author":"Orme","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib56","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/cpt1974154424","article-title":"Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man","volume":"15","author":"Breckenridge","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0670_bib57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/cpt1974162348","article-title":"Studies on the optical enantiomorphs of warfarin in man","volume":"16","author":"O'Reilly","year":"1974","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0670_bib58","first-page":"545","article-title":"Stereoselective interaction of phenylbutazone with 13C\/12C labelled racemates of warfarin in man [abstract]","volume":"37","author":"O'Reilly","year":"1978","journal-title":"Fed Proc"},{"key":"10.1378\/chest.08-0670_bib59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/clpt.1986.3","article-title":"The warfarin-sulfinpyrazone interaction: stereochemical considerations","volume":"39","author":"Toon","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0670_bib60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJM197608122950702","article-title":"The stereoselective interaction of warfarin and metronidazole in man","volume":"295","author":"O'Reilly","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJM198001033020106","article-title":"Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man","volume":"302","author":"O'Reilly","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib62","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1172\/JCI107711","article-title":"Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone","volume":"53","author":"Lewis","year":"1974","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.08-0670_bib63","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/clpt.1987.149","article-title":"Interaction of amiodarone with racemic warfarin and its separated enantimorphs in humans","volume":"42","author":"O'Reilly","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0670_bib64","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.1981.00340040054017","article-title":"Lack of effect of fortified wine ingested during fasting and anticoagulant therapy","volume":"141","author":"O'Reilly","year":"1981","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib65","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/j.1875-9114.1997.tb03782.x","article-title":"A review of enzyme induction of warfarin metabolism with recommendations for patient management","volume":"17","author":"Cropp","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.08-0670_bib66","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1055\/s-0038-1661101","article-title":"Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins","volume":"51","author":"Bechtold","year":"1984","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.1983.03330250049027","article-title":"Prolonged bleeding times and bleeding diathesis associated with moxalactam administration","volume":"249","author":"Weitkamp","year":"1983","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0670_bib68","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM196201112660205","article-title":"Effect of sodium dextro-thyroxine in patients receiving anticoagulants","volume":"266","author":"Owens","year":"1962","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib69","first-page":"309","article-title":"Studies on the interaction of warfarin and clofibrate in man","volume":"27","author":"O'Reilly","year":"1972","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1378\/chest.08-0670_bib70","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cpt1979262145","article-title":"Commentary: hematological perturbations associated with salicylate","volume":"26","author":"Rothschild","year":"1979","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0670_bib71","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.279.9.657","article-title":"Acetaminophen and other risk factors for excessive warfarin anticoagulation","volume":"279","author":"Hylek","year":"1998","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0670_bib72","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/jama.279.9.702","article-title":"Acetaminophen and warfarin: undesirable synergy","volume":"279","author":"Bell","year":"1998","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0670_bib73","first-page":"1621","article-title":"Interaction between paracetamol and warfarin in patients: a double-blind, placebo- controlled, randomized study","volume":"91","author":"Mahe","year":"2006","journal-title":"Haematologica"},{"key":"10.1378\/chest.08-0670_bib74","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1160\/TH04-02-0109","article-title":"Paracetamol (acetaminophen) warfarin interaction: nAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle","volume":"92","author":"Thijssen","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib75","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1160\/TH04-08-0472","article-title":"Paracetamol (acetaminophen) and warfarin interaction: unraveling the pivotal role of the vitamin K cycle","volume":"92","author":"Hylek","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib76","first-page":"210","article-title":"Effect of erythromycin in patients receiving long-term warfarin therapy","volume":"8","author":"Weibert","year":"1989","journal-title":"Clin Pharm"},{"key":"10.1378\/chest.08-0670_bib77","first-page":"332","article-title":"Potentiation of warfarin anticoagulation by topical testosterone treatment","volume":"4","author":"Lorentz","year":"1985","journal-title":"Clin Pharm"},{"key":"10.1378\/chest.08-0670_bib78","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jama.1965.03090150019004","article-title":"Human sources and absorption of vitamin K in relation to anticoagulation","volume":"194","author":"Udall","year":"1965","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0670_bib79","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/0002-8703(80)90625-0","article-title":"Bleeding during acetysalicylic acid and anticoagulant therapy in patients with reduced platelet reactivity after aortic valve replacement","volume":"99","author":"Dale","year":"1980","journal-title":"Am Heart J"},{"key":"10.1378\/chest.08-0670_bib80","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/28.1.46","article-title":"Interaction of ibuprofen and warfarin on primary haemostasis","volume":"38","author":"Schulman","year":"1989","journal-title":"Br J Rheumatol"},{"key":"10.1378\/chest.08-0670_bib81","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/archinte.165.2.189","article-title":"Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors","volume":"165","author":"Battistella","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib82","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3181\/00379727-142-36980","article-title":"Effects of penicillin G on platelet aggregation, release and adherence to collagen","volume":"142","author":"Cazenave","year":"1973","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1378\/chest.08-0670_bib83","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM197408082910601","article-title":"The hemostatic defect produced by carbenicillin","volume":"291","author":"Brown","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib84","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particulate fraction protein","volume":"56","author":"Roth","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.08-0670_bib85","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.08-0670_bib86","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/0002-9149(83)90673-2","article-title":"Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole","volume":"51","author":"Chesebro","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.08-0670_bib87","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJM199308193290802","article-title":"Aspirin and warfarin after heart-valve replacement: a comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement","volume":"329","author":"Turpie","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib88","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib89","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1538-7836.2007.02391.x","article-title":"Dietary supplement use among anticoagulation clinic patients","volume":"5","author":"Wittkowsky","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib90","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1012742628628","article-title":"Drug interactions updates: drugs, herbs and oral anticoagulation","volume":"12","author":"Wittkowsky","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib91","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/0091270004271404","article-title":"Interaction of warfarin with drugs, natural substances and foods","volume":"45","author":"Greenblatt","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1378\/chest.08-0670_bib92","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1160\/TH04-05-0285","article-title":"Herbal remedies and anticoagulant therapy","volume":"93","author":"Samuels","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2003.06.039","article-title":"Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction","volume":"98","author":"Izzo","year":"2005","journal-title":"Int J Cardiol"},{"key":"10.1378\/chest.08-0670_bib94","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2125.2005.02322.x","article-title":"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects","volume":"59","author":"Jiang","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1378\/chest.08-0670_bib95","first-page":"1076","article-title":"Effect of coenzyme Q10 and ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients: a randomized, double blind, placebo-crossover trial","volume":"87","author":"Engelsen","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib96","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-141-1-200407060-00011","article-title":"Brief Communication: American ginseng reduces warfarin's effect in healthy patients","volume":"141","author":"Yuan","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib97","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJM198007173030317","article-title":"Resistance to warfarin due to unrecognized vitamin K supplementation","volume":"303","author":"O'Reilly","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib98","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/ajcn\/47.3.475","article-title":"Vitamin K deficiency from dietary vitamin K restriction in humans","volume":"47","author":"Suttie","year":"1988","journal-title":"Am J Clin Nutr"},{"key":"10.1378\/chest.08-0670_bib99","series-title":"Oral anticoagulants","first-page":"9","article-title":"Structure and mechanism of activation of vitamin K antagonists","author":"Sadowski","year":"1996"},{"key":"10.1378\/chest.08-0670_bib100","series-title":"The heart as a source of systemic embolisation","article-title":"Mechanisms of vitamin K metabolism and vitamin K-dependent hemostasis: implications for warfarin therapy","author":"Bovill","year":"1992"},{"key":"10.1378\/chest.08-0670_bib101","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-0038-1655997","article-title":"Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with a constant vitamin K1 content","volume":"77","author":"Booth","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib102","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1126\/science.97.2518.313","article-title":"Influence of fever upon the action of 3,3methylene bis-(4-hydroxoycoumarin)","volume":"97","author":"Richards","year":"1943","journal-title":"Science"},{"key":"10.1378\/chest.08-0670_bib103","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM198409063111007","article-title":"Warfarin: from bedside to bench","volume":"311","author":"Wessler","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib104","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1172\/JCI116814","article-title":"Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin-K dependent clotting factors","volume":"92","author":"Zivelin","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.08-0670_bib105","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1203\/00006450-199605000-00014","article-title":"Decreased thrombin activity of fibrin clots prepared in cord plasma compared to adult plasma","volume":"39","author":"Patel","year":"1996","journal-title":"Pediatr Res"},{"key":"10.1378\/chest.08-0670_bib106","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1172\/JCI114723","article-title":"Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors","volume":"86","author":"Weitz","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1378\/chest.08-0670_bib107","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V75.2.344.344","article-title":"Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring anticoagulant therapy","volume":"75","author":"Furie","year":"1990","journal-title":"Blood"},{"key":"10.1378\/chest.08-0670_bib108","first-page":"73","article-title":"The prothrombin time in haemophilia and in obstructive jaundice","volume":"109","author":"Quick","year":"1935","journal-title":"J Biol Chem"},{"key":"10.1378\/chest.08-0670_bib109","first-page":"225","article-title":"Progress in standarisation in anticoagulant control","volume":"1","author":"Poller","year":"1987","journal-title":"Hematol Rev"},{"key":"10.1378\/chest.08-0670_bib110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1055\/s-0038-1657371","article-title":"Calibration of reference thromboplastins and standardisation of the prothrombin time ratio","volume":"49","author":"Kirkwood","year":"1983","journal-title":"Thromb Haemost"},{"issue":"119(suppl)","key":"10.1378\/chest.08-0670_bib111","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","article-title":"Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.08-0670_bib112","unstructured":"World Health Organization Expert Committee on Biological Standardization. 33rd report: technical report series No. 687. Geneva, Switzerland: World Health Organization, 1983"},{"key":"10.1378\/chest.08-0670_bib113","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0022-2143(96)90014-1","article-title":"Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio","volume":"128","author":"Johnston","year":"1996","journal-title":"J Lab Clin Med"},{"key":"10.1378\/chest.08-0670_bib114","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0038-1642513","article-title":"Assessment of the validity of the INR system for patients with liver impairment","volume":"71","author":"Kovacs","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1055\/s-0038-1653742","article-title":"Validity of the INR system for patients with liver impairment","volume":"73","author":"Denson","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib116","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.510240613","article-title":"Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?","volume":"24","author":"Robert","year":"1996","journal-title":"Hepatology"},{"key":"10.1378\/chest.08-0670_bib117","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/jhep.2000.18711","article-title":"Normalizing the prothrombin time","volume":"32","author":"Malinchoc","year":"2000","journal-title":"Hepatology"},{"key":"10.1378\/chest.08-0670_bib118","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00001721-199907000-00001","article-title":"Clinically significant differences in the international normalized ratio measured with reagents of different sensitivities","volume":"10","author":"Lind","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.08-0670_bib119","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1055\/s-0038-1651019","article-title":"The effect of some instruments for prothrombin time testing on the international sensitivity index (ISI) of two rabbit tissue thromboplastin reagents","volume":"62","author":"Poggio","year":"1989","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ajcp\/92.3.321","article-title":"Comparison of two automated coagulometers and the manual tilt tube method for determination of prothrombin time","volume":"92","author":"D'Angelo","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib121","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/jcp.42.1.97","article-title":"Effect of automation on the prothrombin time test in NEQAS surveys","volume":"42","author":"Poller","year":"1989","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib122","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1055\/s-0038-1645059","article-title":"The dependence of the international sensitivity index on the coagulometer used to perform the prothrombin time","volume":"63","author":"Ray","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib123","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/clinchem\/35.5.840","article-title":"Correction of instrument and reagent based differences in determination of the international normalized ratio (INR) for monitoring anticoagulant therapy","volume":"355","author":"Van Rijn","year":"1989","journal-title":"Clin Chem"},{"key":"10.1378\/chest.08-0670_bib124","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/jcp.43.8.679","article-title":"Automation and prothrombin time: a United Kingdom field study of two widely used coagulometers","volume":"43","author":"Thomson","year":"1990","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib125","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ajhp\/58.8.684","article-title":"Clinical impact of inter-laboratory variation in international normalized ratio determinations","volume":"58","author":"Kinck","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1378\/chest.08-0670_bib126","first-page":"I620","article-title":"Significant variation in the reporting of prothrombin time results despite utilization of the INR method of reporting [abstract]","volume":"100","author":"Jacobson","year":"1999","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0670_bib127","first-page":"768","article-title":"College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy","volume":"122","author":"Fairweather","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"10.1378\/chest.08-0670_bib128","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/ajcp\/99.6.689","article-title":"Failure of the international normalized ratio to generate consistent results within a local medical community","volume":"99","author":"Ng","year":"1993","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib129","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/bmj.294.6581.1184","article-title":"Laboratory control of oral anticoagulants [editorial]","volume":"294","author":"Poller","year":"1987","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0670_bib130","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-0038-1647353","article-title":"Evaluation of international normalized ratios by a controlled field survey with 4 different thromboplastin reagents","volume":"64","author":"Kazama","year":"1990","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib131","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-0038-1651553","article-title":"Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time: a report of the Subcommittee for Control of Anticoagulation","volume":"69","author":"Van Den Besselaar","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib132","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-0038-1648816","article-title":"Effect of concentration of trisodium citrate anticoagulant on calculation of the international normalized ratio and the international sensitivity index of thromboplastin","volume":"72","author":"Duncan","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib133","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ajcp\/107.1.105","article-title":"Effect of 3.2% vs. 3.8% sodium citrate on routine coagulation testing","volume":"107","author":"Adcock","year":"1997","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib134","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/oxfordjournals.eurheartj.a060739","article-title":"Guidelines for prevention of thromboembolic events in valvular heart disease: study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology","volume":"16","author":"Gohlke-Barwolf","year":"1995","journal-title":"Eur Heart J"},{"issue":"126(suppl)","key":"10.1378\/chest.08-0670_bib135","doi-asserted-by":"crossref","first-page":"457S","DOI":"10.1378\/chest.126.3_suppl.457S","article-title":"Antithrombotic therapy in valvular heart disease: native and prosthetic","author":"Salem","year":"2004","journal-title":"Chest"},{"key":"10.1378\/chest.08-0670_bib136","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0002-9343(89)80690-4","article-title":"Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions","volume":"87","author":"Landefeld","year":"1989","journal-title":"Am J Med"},{"key":"10.1378\/chest.08-0670_bib137","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-118-7-199304010-00005","article-title":"Risk factors for complications of chronic anticoagulation: a multi-center study; Warfarin Optimized Outpatient Follow-up Study Group","volume":"118","author":"Fihn","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib138","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199507063330103","article-title":"Optimal oral anticoagulant therapy in patients with mechanical heart valves","volume":"333","author":"Cannegieter","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib139","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib140","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISOCOAT): Italian Study on Complications of Oral Anticoagulant Therapy","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib141","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199608223350802","article-title":"An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation","volume":"335","author":"Hylek","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib142","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198212303072704","article-title":"Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis","volume":"307","author":"Hull","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib143","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/S0140-6736(88)92070-3","article-title":"Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement","volume":"1","author":"Turpie","year":"1988","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib144","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJM199002153220703","article-title":"Trial of different intensities of anticoagulation in patients with prosthetic heart valves","volume":"322","author":"Saour","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib145","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0022-5223(19)36724-8","article-title":"Comparison of two levels of anticoagulant therapy in patients with substitute heart valves","volume":"101","author":"Altman","year":"1991","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1378\/chest.08-0670_bib146","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1378\/chest.127.1.53","article-title":"Thromboembolic and bleeding complications following St. Jude mechanical valve replacement","volume":"127","author":"Hering","year":"2005","journal-title":"Chest"},{"issue":"3(suppl)","key":"10.1378\/chest.08-0670_bib147","doi-asserted-by":"crossref","first-page":"Q39","DOI":"10.1016\/S1520-765X(01)90041-0","article-title":"Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5)","author":"Pruefer","year":"2001","journal-title":"Eur Heart J Suppl"},{"key":"10.1378\/chest.08-0670_bib148","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.athoracsur.2004.09.012","article-title":"Low-dose International Normalized Ratio self-management: a promising tool to achieve low complicated rates after mechanical valve replacement","volume":"79","author":"Koertke","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"10.1378\/chest.08-0670_bib149","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/ncpcardio0271","article-title":"Drug insight: an overview of current anticoagulation therapy after heart valve replacement","volume":"2","author":"Hering","year":"2005","journal-title":"Nat Clin Prac Cardiovasc Med"},{"issue":"126(suppl)","key":"10.1378\/chest.08-0670_bib150","doi-asserted-by":"crossref","first-page":"457S","DOI":"10.1378\/chest.126.3_suppl.457S","article-title":"Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","author":"Salem","year":"2004","journal-title":"Chest"},{"key":"10.1378\/chest.08-0670_bib151","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.106.176857","volume":"114","year":"2006","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0670_bib152","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib153","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","article-title":"Comparison of low-intensity warfarin therapy with conventional intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism","volume":"349","author":"Kearon","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib154","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1001\/jama.282.21.2058","article-title":"Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis","volume":"282","author":"Anand","year":"1999","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0670_bib155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1046\/j.1525-1497.2000.04329.x","article-title":"Prevention of thromboembolism in atrial fibrillation: a meta-analysis of trials of anticoagulants and antiplatelet drugs","volume":"15","author":"Segal","year":"2000","journal-title":"J Gen Intern Med"},{"key":"10.1378\/chest.08-0670_bib156","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib157","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","volume":"154","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib158","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.410420606","volume":"42","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1378\/chest.08-0670_bib159","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1055\/s-0038-1665430","article-title":"Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: iSCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy)","volume":"78","author":"Palareti","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib160","series-title":"Clinical epidemiology: a basic science for clinical medicine","first-page":"283","author":"Sackett","year":"1991"},{"key":"10.1378\/chest.08-0670_bib161","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/0003-4819-76-3-112-6-423","article-title":"Very low doses of warfarin can prevent thrombosis in central venous catheters","volume":"112","author":"Bern","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib162","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0959-8049(97)89012-0","article-title":"A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy","volume":"33","author":"Nightingale","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1378\/chest.08-0670_bib163","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1365-2141.1998.00732.x","article-title":"Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies","volume":"101","author":"Boraks","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.08-0670_bib164","first-page":"703a","article-title":"A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer [abstract]","volume":"100","author":"Couban","year":"2002","journal-title":"Blood"},{"key":"10.1378\/chest.08-0670_bib165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1445-5994.2002.00171.x","article-title":"Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis","volume":"32","author":"Heaton","year":"2002","journal-title":"Intern Med J"},{"key":"10.1378\/chest.08-0670_bib166","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.303.6796.224","article-title":"Prevention of venous thrombosis with minidose warfarin after joint replacement","volume":"303","author":"Dale","year":"1991","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0670_bib167","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.303.6796.219","article-title":"Efficacy of fixed minidose warfarin prophylaxis in total hip replacement","volume":"303","author":"Fordyce","year":"1991","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0670_bib168","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/107602969500100404","article-title":"Minidose warfarin and failure to prevent deep vein thrombosis after joint replacement surgery despite inhibiting the postoperative rise in plasminogen activator inhibitor activity","volume":"1","author":"Poller","year":"1995","journal-title":"Clin Appl Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib169","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archinte.158.14.1513","article-title":"Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study (the AFASAK-2 study)","volume":"158","author":"Gull\u00f8v","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib170","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(97)01180-X","volume":"350","year":"1997","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib171","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(89)91200-2","article-title":"Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study","volume":"1","author":"Petersen","year":"1989","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib172","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","volume":"323","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib173","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib174","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","volume":"84","year":"1991","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0670_bib175","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib176","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/hrt.2004.058339","article-title":"Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvular atrial fibrillation in the general population when treated and untreated with warfarin","volume":"92","author":"Currie","year":"2006","journal-title":"Heart"},{"key":"10.1378\/chest.08-0670_bib177","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.thromres.2004.11.025","article-title":"Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal","volume":"117","author":"Oden","year":"2006","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0670_bib178","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/eurheartj\/ehl176","volume":"27","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.08-0670_bib179","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib180","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib181","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2796.2005.01512.x","article-title":"Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation","volume":"258","author":"Indredavik","year":"2005","journal-title":"J Intern Med"},{"key":"10.1378\/chest.08-0670_bib182","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(06)70536-1","article-title":"Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study","volume":"5","author":"O'Donnell","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1378\/chest.08-0670_bib183","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","article-title":"Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomized controlled trial","volume":"360","author":"Van Es","year":"2002","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib184","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib185","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/hc0502.103329","article-title":"Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study","volume":"105","author":"Fiore","year":"2002","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0670_bib186","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0735-1097(00)01118-9","volume":"37","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"suppl","key":"10.1378\/chest.08-0670_bib187","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists","volume":"126","author":"Ansell","year":"2004","journal-title":"Chest"},{"key":"10.1378\/chest.08-0670_bib188","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/106002809703100516","article-title":"Consensus guidelines for coordinated outpatient oral anticoagulation therapy management","volume":"31","author":"Ansell","year":"1997","journal-title":"Ann Pharmacother"},{"key":"10.1378\/chest.08-0670_bib189","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2141.2005.05417.x","article-title":"Risk factors for highly unstable response to oral anticoagulation: a case-control study","volume":"129","author":"Palareti","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.08-0670_bib190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-126-2-199701150-00006","article-title":"Comparison of 5 mg and 10 mg loading doses in initiation of warfarin therapy","volume":"126","author":"Harrison","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib191","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1161\/01.CIR.38.1.169","article-title":"Studies on coumarin anticoagulant drugs: initiation of warfarin therapy with a loading dose","volume":"38","author":"O'Reilly","year":"1968","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0670_bib192","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/archinte.159.1.46","article-title":"A randomized trial comparing 5 mg and 10 mg warfarin loading doses","volume":"159","author":"Crowther","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib193","doi-asserted-by":"crossref","first-page":"714","DOI":"10.7326\/0003-4819-138-9-200305060-00007","article-title":"Comparison of 10 mg and 5 mg warfarin initiation nomograms together with low molecular weight heparin for outpatient treatment of acute venous thromboembolism","volume":"138","author":"Kovacs","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib194","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0002-9149(01)01582-X","article-title":"Comparison of a daily fixed 2.5 mg warfarin dose with a 5 mg, International Normalized ratio adjusted, warfarin dose initially following heart valve replacement","volume":"88","author":"Ageno","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1378\/chest.08-0670_bib195","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1378\/chest.127.6.2049","article-title":"Warfarin maintenance dosing patterns in clinical practice","volume":"127","author":"Garcia","year":"2005","journal-title":"Chest"},{"key":"10.1378\/chest.08-0670_bib196","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1160\/TH04-02-0083","article-title":"Warfarin dosing and cytochrome P450 2C9 polymorphisms","volume":"91","author":"Joffe","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib197","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1160\/TH03-06-0379","article-title":"Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin","volume":"91","author":"Gage","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib198","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.clpt.2004.01.007","article-title":"CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences","volume":"75","author":"Takahashi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0670_bib199","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1160\/TH05-03-0690","article-title":"Vitamin K epoxide reductase genetic polymorphism is associated to oral anticoagulant overdose","volume":"94","author":"Quteineh","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH05-06-0446","article-title":"Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin","volume":"95","author":"Vecsler","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib201","doi-asserted-by":"crossref","first-page":"749","DOI":"10.7326\/0003-4819-145-10-200611210-00007","article-title":"Pharmacogenomics: challenges and opportunities","volume":"145","author":"Roden","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib202","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3121\/cmr.3.3.137","article-title":"A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data","volume":"3","author":"Hillman","year":"2005","journal-title":"Clin Med Res"},{"key":"10.1378\/chest.08-0670_bib203","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1160\/TH04-08-0542","article-title":"Prospective dosing of warfarin based on cytochrome P 450 2C9 genotype","volume":"93","author":"Voora","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib204","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1055\/s-0038-1657628","article-title":"Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment","volume":"78","author":"Sallah","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib205","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1592\/phco.19.18.1385.30894","article-title":"Influence of warfarin regimen type on clinical and monitoring outcomes in stable patients in an anticoagulation management service","volume":"19","author":"Wong","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.08-0670_bib206","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/107602960100700108","article-title":"Effect of regimen complexity on patient satisfaction and compliance with warfarin therapy","volume":"7","author":"Hixson-Wallace","year":"2001","journal-title":"Clin Appl Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib207","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7326\/0003-4819-116-11-901","article-title":"Aging and the anticoagulant response to warfarin therapy","volume":"116","author":"Gurwitz","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib208","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/ageing\/20.3.217","article-title":"The association of age with dosage requirement for warfarin","volume":"20","author":"Redwood","year":"1991","journal-title":"Age Ageing"},{"key":"10.1378\/chest.08-0670_bib209","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/jcp.45.8.704","article-title":"Factors affecting the maintenance dose of warfarin","volume":"45","author":"James","year":"1992","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib210","first-page":"878","article-title":"Aging and warfarin therapy. Annual Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"117","author":"Mungall","year":"1992","journal-title":"Intern Med"},{"key":"10.1378\/chest.08-0670_bib211","first-page":"172","article-title":"Stereoselective disposition of warfarin in young and elderly subjects [abstract]","volume":"55","author":"Bowles","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1378\/chest.08-0670_bib212","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.amjmed.2004.07.053","article-title":"Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen","volume":"118","author":"Siguret","year":"2005","journal-title":"Am J Med"},{"key":"10.1378\/chest.08-0670_bib213","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1592\/phco.20.11.923.35260","article-title":"Evaluation of warfarin initiation regimens in elderly inpatients","volume":"20","author":"O'Connell","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.08-0670_bib214","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1008884004751","article-title":"Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use","volume":"7","author":"McCormick","year":"1999","journal-title":"J Thromb Thrombolysis"},{"issue":"5(suppl)","key":"10.1378\/chest.08-0670_bib215","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1023\/A:1013228718768","article-title":"Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease","author":"Horstkotte","year":"1998","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib216","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1023\/A:1018778914477","article-title":"Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management","volume":"9","author":"Samsa","year":"2000","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib217","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/0272989X9201200206","article-title":"A model for planning optimal follow-up for outpatients on warfarin anticoagulation","volume":"12","author":"Kent","year":"1992","journal-title":"Med Decis Making"},{"key":"10.1378\/chest.08-0670_bib218","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1309\/U7164E0XH5UERKRV","article-title":"A comparison between six-and four-week intervals in surveillance of oral anticoagulant treatment","volume":"120","author":"Pengo","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib219","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.thromres.2006.10.001","article-title":"The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation","volume":"120","author":"Shalev","year":"2007","journal-title":"Thromb Res"},{"issue":"suppl","key":"10.1378\/chest.08-0670_bib220","first-page":"676","article-title":"Frequent prothrombin time testing reduces inappropriate warfarin dose changes [abstract]","volume":"82","author":"Gunneman","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib221","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/archinte.158.5.528","article-title":"Evaluation of excessive anticoagulation in a group model health maintenance organization","volume":"158","author":"Lousberg","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib222","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacc.2005.09.058","article-title":"The risk of hemorrhage among patients with warfarin-associated coagulopathy","volume":"47","author":"Garcia","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.08-0670_bib223","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-135-6-200109180-00008","article-title":"Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin","volume":"135","author":"Hylek","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib224","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1055\/s-0038-1655992","article-title":"Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy","volume":"77","author":"Makris","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib225","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2257.1998.00161.x","article-title":"Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal","volume":"20","author":"Nitu","year":"1998","journal-title":"Clin Lab Haematol"},{"key":"10.1378\/chest.08-0670_bib226","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7326\/0003-4819-137-11-200212030-00009","article-title":"Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate","volume":"137","author":"Deveras","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib227","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-2000-8464","article-title":"Recombinant FVIIa in the treatment of warfarin bleeding","volume":"26","author":"Berntorp","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.08-0670_bib228","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00001721-200307000-00007","article-title":"Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects","volume":"14","author":"Sorensen","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.08-0670_bib229","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1160\/TH05-01-0032","article-title":"Recombinant factor VIIa: an update on its clinical use","volume":"93","author":"Franchini","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib230","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00001721-199811000-00003","article-title":"The effect of recombinant factor VIIa in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0","volume":"9","author":"Erhardtsen","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.08-0670_bib231","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(00)03125-1","article-title":"Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomized trial","volume":"356","author":"Crowther","year":"2000","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib232","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jacc.2005.05.022","article-title":"A randomized trial comparing 1 mg of oral vitamin K with no treatment in the management of warfarin-associated coagulopathy in patients with mechanical heart valves","volume":"46","author":"Ageno","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.08-0670_bib233","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.thromres.2004.03.004","article-title":"Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR > 10","volume":"113","author":"Gunther","year":"2004","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0670_bib234","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1001\/archinte.158.19.2136","article-title":"Comparing different routes and doses of phytonadione for reversing excessive anticoagulation","volume":"158","author":"Whitling","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib235","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1001\/archinte.159.22.2721","article-title":"Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione","volume":"159","author":"Raj","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib236","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-137-4-200208200-00009","article-title":"Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin associated coagulopathy","volume":"137","author":"Crowther","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib237","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00001721-199304050-00010","article-title":"Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation","volume":"4","author":"Pengo","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.08-0670_bib238","first-page":"12","article-title":"The effectiveness of an oral vitamin K1 in controlling excessive hypoprothrombinemia during anticoagulant therapy","volume":"45","author":"Cosgriff","year":"1956","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib239","first-page":"453","article-title":"Small doses of vitamin K1 for correction of reduced prothrombin activity","volume":"34","author":"Shirger","year":"1959","journal-title":"Proc Staff Meet Mayo Clin"},{"key":"10.1378\/chest.08-0670_bib240","doi-asserted-by":"crossref","first-page":"959","DOI":"10.7326\/0003-4819-126-12-199706150-00005","article-title":"Correction of excessive anticoagulation with low dose oral vitamin K1","volume":"125","author":"Weibert","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib241","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1055\/s-0038-1648371","article-title":"Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1","volume":"67","author":"Shetty","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib242","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5694\/j.1326-5377.1991.tb94070.x","article-title":"Anaphylactoid reactions and vitamin K [letter]","volume":"155","author":"Martin","year":"1991","journal-title":"Med J Aust"},{"key":"10.1378\/chest.08-0670_bib243","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1011237019082","article-title":"Anaphylactoid reactions to vitamin K","volume":"11","author":"Fiore","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib244","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2141.2001.03070.x","article-title":"A comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarin","volume":"115","author":"Watson","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.08-0670_bib245","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0025-6196(11)60970-1","article-title":"Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion","volume":"82","author":"Aguilar","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1378\/chest.08-0670_bib246","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.thromres.2004.09.002","article-title":"Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation","volume":"115","author":"Yasaka","year":"2005","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0670_bib247","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1592\/phco.26.8.1091","article-title":"Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin","volume":"26","author":"Dager","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.08-0670_bib248","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJMoa042991","article-title":"Recombinant activated factor VII for acute intracererbral hemorrhage","volume":"352","author":"Mayer","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib249","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2516.2002.00532.x","article-title":"Safety of factor VIII inhibitor bypass activity (FEIBA): 10 year compilation of thrombotic adverse events","volume":"8","author":"Ehrlich","year":"2002","journal-title":"Haemophilia"},{"key":"10.1378\/chest.08-0670_bib250","first-page":"77","article-title":"Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal","volume":"23","author":"Sorano","year":"1993","journal-title":"Haemostasis"},{"key":"10.1378\/chest.08-0670_bib251","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1160\/TH04-12-0773","article-title":"Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation","volume":"93","author":"Sconce","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib252","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1160\/TH04-06-0346","article-title":"Over- the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1- depleted patients","volume":"92","author":"Kurnik","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib253","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2004-04-1525","article-title":"Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects","volume":"104","author":"Schurgers","year":"2004","journal-title":"Blood"},{"key":"10.1378\/chest.08-0670_bib254","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1592\/phco.2005.25.12.1746","article-title":"Low-dose vitamin K to augment anticoagulation control","volume":"25","author":"Reese","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.08-0670_bib255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11239-007-0014-z","article-title":"Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios","volume":"24","author":"Ford","year":"2007","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib256","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood-2006-09-049262","article-title":"Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin","volume":"109","author":"Sconce","year":"2007","journal-title":"Blood"},{"key":"10.1378\/chest.08-0670_bib257","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199705223362107","article-title":"Management of anticoagulation before and after elective surgery","volume":"336","author":"Kearon","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib258","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/archinte.163.8.901","article-title":"Perioperative management of patients on oral anticoagulants: a systematic review","volume":"163","author":"Dunn","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib259","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","article-title":"Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients","volume":"117","author":"Rosove","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib260","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid-antibody syndrome","volume":"332","author":"Khamashta","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib261","first-page":"62","article-title":"Falsely elevated INRs in warfarin-treated patients with the lupus anticoagulant","volume":"99","author":"Sanfelippo","year":"2000","journal-title":"Wis Med J"},{"key":"10.1378\/chest.08-0670_bib262","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-127-3-199708010-00001","article-title":"Monitoring warfarin therapy in patients with lupus anticoagulants","volume":"127","author":"Moll","year":"1997","journal-title":"Ann Intern Med"},{"issue":"suppl","key":"10.1378\/chest.08-0670_bib263","first-page":"10","article-title":"Potential failure of the international normalized ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants","volume":"147","author":"Della Valle","year":"1996","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1378\/chest.08-0670_bib264","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1055\/s-0037-1615146","article-title":"Control of oral anticoagulation in patients with the antiphospholipid syndrome: influence of the lupus anticoagulant on international normalized ratio","volume":"80","author":"Robert","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib265","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1046\/j.1365-2141.1997.3283145.x","article-title":"Monitoring of oral anticoagulant therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome","volume":"98","author":"Lawrie","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.08-0670_bib266","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM199509073331016","article-title":"Thrombosis in the antiphospholipid antibody syndrome [letter]","volume":"333","author":"Rapaport","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib267","doi-asserted-by":"crossref","first-page":"552","DOI":"10.7326\/0003-4819-120-7-199404010-00004","article-title":"The international normalized ratio (INR) for monitoring warfarin therapy: reliability and relation to other monitoring methods","volume":"120","author":"Le","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib268","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00001721-199701000-00008","article-title":"Plasma levels of factors II, VII, and X and their relationship to the international normalized ratio during chronic warfarin therapy:","volume":"8","author":"Lind","year":"1997","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1378\/chest.08-0670_bib269","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1161\/01.CIR.88.2.454","article-title":"Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis","volume":"88","author":"Kornbert","year":"1993","journal-title":"Circulation"},{"key":"10.1378\/chest.08-0670_bib270","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib271","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib272","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1160\/TH04-11-0723","article-title":"Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation","volume":"93","author":"Ames","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib273","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1160\/TH06-02-0090","article-title":"Warfarin-related outcomes in patients with antiphospholipid antibody syndrome managed in an anticoagulation clinic","volume":"96","author":"Wittkowsky","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib274","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199507063330102","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib275","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(89)80689-8","article-title":"Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy","volume":"87","author":"Landefeld","year":"1989","journal-title":"Am J Med"},{"key":"10.1378\/chest.08-0670_bib276","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archinte.1993.00410130073007","article-title":"Bleeding complications in oral anticoagulant therapy: an analysis of risk factors","volume":"153","author":"Van Der Meer","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib277","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-8703(82)90292-7","article-title":"Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio","volume":"103","author":"Forfar","year":"1982","journal-title":"Am Heart J"},{"key":"10.1378\/chest.08-0670_bib278","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib279","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0167-5273(88)90165-9","article-title":"Anticoagulation clinics and the monitoring of anticoagulant therapy","volume":"18","author":"Charney","year":"1988","journal-title":"Int J Cardiol"},{"key":"10.1378\/chest.08-0670_bib280","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1378\/chest.100.6.1553","article-title":"Low intensity anticoagulation in mechanical cardiac prosthetic valves","volume":"100","author":"Wilson","year":"1991","journal-title":"Chest"},{"key":"10.1378\/chest.08-0670_bib281","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0735-1097(91)90585-W","article-title":"Canadian Atrial Fibrillation Anticoagulation (CAFA) study","volume":"18","author":"Connolly","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1378\/chest.08-0670_bib282","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1538-7836.2005.01330.x","article-title":"Poor anticoagulation quality in the first three months after unprovoked venous thromboembolism is a risk factor for long-term recurrence","volume":"3","author":"Palareti","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib283","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/0003-4819-133-9-200011070-00010","article-title":"A multi-component intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial","volume":"133","author":"Beyth","year":"2000","journal-title":"Ann Intern Med"},{"issue":"17(suppl)","key":"10.1378\/chest.08-0670_bib284","first-page":"230","article-title":"Improvement of prognosis by home prothrombin estimation in patients with life-long anticoagulant therapy [abstract]","author":"Horstkotte","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.08-0670_bib285","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.281.2.145","article-title":"A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial; Working Group for the Study of Patient Self-Management of Oral Anticoagulation","volume":"281","author":"Sawicki","year":"1999","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0670_bib286","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0003-4975(01)02656-X","article-title":"International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous?","volume":"72","author":"Kortke","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"10.1378\/chest.08-0670_bib287","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0002-9343(02)01131-2","article-title":"Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial","volume":"113","author":"Matchar","year":"2002","journal-title":"Am J Med"},{"key":"10.1378\/chest.08-0670_bib288","first-page":"293","article-title":"Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial","volume":"169","author":"Wilson","year":"2003","journal-title":"Can Med Assoc J"},{"key":"10.1378\/chest.08-0670_bib289","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1001\/archinte.163.21.2639","article-title":"Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands","volume":"163","author":"Gadisseur","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib290","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0140-6736(00)02470-3","article-title":"Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomized cross-over comparison","volume":"556","author":"Cromheecke","year":"2000","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib291","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1055\/s-0037-1613888","article-title":"A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation","volume":"83","author":"Watzke","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib292","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.clinthera.2004.09.002","article-title":"Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic","volume":"26","author":"Abdelhafiz","year":"2004","journal-title":"Clin Ther"},{"key":"10.1378\/chest.08-0670_bib293","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-142-1-200501040-00006","article-title":"Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial","volume":"142","author":"Menendez-Jandula","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib294","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/jcp.55.11.845","article-title":"A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management","volume":"55","author":"Fitzmaurice","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib295","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1055\/s-2007-996435","article-title":"The effect of self-monitoring the INR on quality of anticoagulation and quality of life","volume":"25","author":"Kulinna","year":"1999","journal-title":"Semin Thromb Hemost"},{"key":"10.1378\/chest.08-0670_bib296","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0049-3848(00)00181-X","article-title":"Clinical outcome of self-management of oral anticoagulation in patients with atrial fibrillation or deep vein thrombosis","volume":"98","author":"Heidinger","year":"2000","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0670_bib297","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/bmj.38618.580903.AE","article-title":"Self management of oral anticoagulation: randomised trial","volume":"331","author":"Fitzmaurice","year":"2005","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0670_bib298","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJM199007193230302","article-title":"The effect of warfarin on mortality and reinfarction after myocardial infarction","volume":"323","author":"Smith","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib299","first-page":"499","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib300","first-page":"687","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib301","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/bmj.319.7215.958","article-title":"Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomized controlled trial comparing two intensities of coumarin with aspirin","volume":"319","author":"Hellemons","year":"1999","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0670_bib302","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1055\/s-0037-1614372","article-title":"Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists","volume":"82","author":"Hutten","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib303","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1067\/mtc.2002.121162","article-title":"Better control improves survival after valve replacement","volume":"123","author":"Butchart","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1378\/chest.08-0670_bib304","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa043033","article-title":"Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis","volume":"352","author":"Chimowitz","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.08-0670_bib305","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","year":"2006","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib306","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib307","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","volume":"293","year":"2005","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0670_bib308","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrmbosis: a randomized trial","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0670_bib309","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/jcp.56.1.48","article-title":"A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation","volume":"56","author":"Fitzmaurice","year":"2003","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib310","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/B:THRO.0000011377.78585.63","article-title":"Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range","volume":"15","author":"Schmitt","year":"2003","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib311","first-page":"236","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"39","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib312","doi-asserted-by":"crossref","first-page":"272a","DOI":"10.1016\/S0735-1097(02)81220-7","article-title":"Comparison of narrow versus standard target INR ranges [abstract]","volume":"39","author":"Meier","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"suppl","key":"10.1378\/chest.08-0670_bib313","first-page":"549","article-title":"The first months of oral anticoagulant treatment are associated with a very low quality of laboratory control: data from the Iscoat Study [abstract]","volume":"82","author":"Palareti","year":"1999","journal-title":"Thromb Haemost"},{"issue":"82(suppl)","key":"10.1378\/chest.08-0670_bib314","first-page":"545","article-title":"Determinants of time spent in the therapeutic range while using vitamin k antagonists [abstract]","author":"Hutten","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib315","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1046\/j.1365-2141.2002.03493.x","article-title":"Therapeutic quality control of oral anticoagulant therapy comparing the short acting acenocoumarol and the long acting phenprocoumon","volume":"117","author":"Gadisseur","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.08-0670_bib316","first-page":"188","article-title":"A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol)","volume":"71","author":"Pattacini","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib317","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin","volume":"105","author":"Beyth","year":"1998","journal-title":"Am J Med"},{"key":"10.1378\/chest.08-0670_bib318","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2796.1991.tb00358.x","article-title":"Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients","volume":"229","author":"Launbjerg","year":"1991","journal-title":"J Intern Med"},{"key":"10.1378\/chest.08-0670_bib319","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/s-0038-1651604","article-title":"Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic","volume":"69","author":"Cortelazzo","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib320","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4065\/70.8.725","article-title":"Bleeding and thromboembolism during anticoagulant therapy: a population based study in Rochester, Minnesota","volume":"70","author":"Gitter","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1378\/chest.08-0670_bib321","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0002-9343(93)90285-W","article-title":"Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention","volume":"95","author":"Landefeld","year":"1993","journal-title":"Am J Med"},{"key":"10.1378\/chest.08-0670_bib322","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1001\/archinte.1984.04400010074014","article-title":"Management of oral anticoagulant therapy: experience with an anticoagulation clinic","volume":"144","author":"Errichetti","year":"1984","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib323","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.410230607","article-title":"Complications of long-term anticoagulation","volume":"23","author":"Petty","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1378\/chest.08-0670_bib324","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/j.1875-9114.1989.tb04128.x","article-title":"The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic","volume":"9","author":"Bussey","year":"1989","journal-title":"Pharmacotherapy"},{"key":"10.1378\/chest.08-0670_bib325","first-page":"62","volume":"I","year":"1982","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib326","first-page":"42","article-title":"The performance of clinics for outpatient control of anticoagulation","volume":"21","author":"McInnes","year":"1987","journal-title":"J R Coll Physicians Lond"},{"key":"10.1378\/chest.08-0670_bib327","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/ageing\/17.6.388","article-title":"Long-term oral anticoagulant therapy in elderly patients","volume":"17","author":"Wickramasinghe","year":"1988","journal-title":"Age Ageing"},{"key":"10.1378\/chest.08-0670_bib328","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/pgmj.64.756.775","article-title":"Can old people on oral anticoagulants be safely managed as outpatients?","volume":"64","author":"Joglekar","year":"1988","journal-title":"Postgrad Med J"},{"key":"10.1378\/chest.08-0670_bib329","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0002-9343(94)90086-8","article-title":"Age-associated risks of prophylactic anticoagulation in the setting of hip fracture","volume":"96","author":"Issacs","year":"1994","journal-title":"Am J Med"},{"key":"10.1378\/chest.08-0670_bib330","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archinte.1977.03630140045012","article-title":"Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting","volume":"137","author":"Davis","year":"1977","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib331","first-page":"273","article-title":"Lack of excessive bleeding risk in elderly patients receiving long-term oral anticoagulation","volume":"3","author":"Graves","year":"1995","journal-title":"Cardiol Elderly"},{"key":"10.1378\/chest.08-0670_bib332","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.161.17.2125","article-title":"Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation","volume":"161","author":"Copland","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib333","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/archinte.1996.00440040081009","volume":"156","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib334","doi-asserted-by":"crossref","first-page":"970","DOI":"10.7326\/0003-4819-124-11-199606010-00004","article-title":"The risk for and severity of bleeding complication in elderly patients treated with warfarin","volume":"124","author":"Fihn","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib335","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2796.1997.tb00023.x","article-title":"Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort","volume":"242","author":"Steffensen","year":"1997","journal-title":"J Intern Med"},{"key":"10.1378\/chest.08-0670_bib336","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0002-9343(86)90260-3","article-title":"Duration of warfarin anticoagulation therapy and the probabilities of recurrent thromboembolism and hemorrhage","volume":"81","author":"Pettiti","year":"1986","journal-title":"Am J Med"},{"key":"10.1378\/chest.08-0670_bib337","first-page":"1155","article-title":"Is age a risk factor for warfarin-related major bleeds in elderly patients with atrial fibrillation?","volume":"54","author":"Cheng","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1378\/chest.08-0670_bib338","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/archinte.160.4.470","article-title":"Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study","volume":"160","author":"Palareti","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib339","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1532-5415.2006.00828.x","article-title":"Age and the risk of warfarin-associated hemorrhage: the Anticoagulation and Risk Factors in Atrial Fibrillation Study","volume":"54","author":"Fang","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1378\/chest.08-0670_bib340","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis","volume":"288","author":"Van Walraven","year":"2002","journal-title":"JAMA"},{"key":"10.1378\/chest.08-0670_bib341","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/archinte.165.13.1527","article-title":"Risks of oral anticoagulant therapy with increasing age","volume":"165","author":"Torn","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib342","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0954-6820.1954.tb01741.x","article-title":"Local hemorrhage and necrosis of the skin and underlying tissues at starting therapy with dicumarol or dicumacyl","volume":"148","author":"Verhagen","year":"1954","journal-title":"Acta Med Scand"},{"key":"10.1378\/chest.08-0670_bib343","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0022-5347(17)51147-7","article-title":"Warfarin necrosis of the skin and subcutaneous tissue of the male genitalia","volume":"130","author":"Weinberg","year":"1983","journal-title":"J Urol"},{"key":"10.1378\/chest.08-0670_bib344","first-page":"244","article-title":"Protein C and the development of skin necrosis during anticoagulant therapy","volume":"49","author":"Broekmans","year":"1983","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib345","doi-asserted-by":"crossref","first-page":"659","DOI":"10.7326\/0003-4819-104-5-659","article-title":"Successful warfarin anticoagulant despite protein C deficiency and a history of warfarin necrosis","volume":"104","author":"Zauber","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib346","first-page":"332","article-title":"Successful progressive anticoagulation in a severe protein C deficiency and previous skin necrosis at the initiation of oral anticoagulation treatment","volume":"51","author":"Samama","year":"1984","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib347","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/bmj.298.6668.233","article-title":"Necrosis of skin induced by coumarin in a patient deficient in protein S","volume":"298","author":"Grimaudo","year":"1989","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0670_bib348","doi-asserted-by":"crossref","first-page":"589","DOI":"10.7326\/0003-4819-135-8_Part_1-200110160-00009","article-title":"Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis","volume":"135","author":"Warkentin","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib349","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/0003-4819-127-9-199711010-00005","article-title":"The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia","volume":"127","author":"Warkentin","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib350","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archinte.164.1.66","article-title":"Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia","volume":"164","author":"Srinivasan","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib351","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/archinte.1974.00320150060006","article-title":"Hemorrhagic complications of anticoagulant therapy","volume":"133","author":"Coon","year":"1974","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib352","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0002-9343(87)90697-8","article-title":"Significance of occult gastrointestinal bleeding during anticoagulation therapy","volume":"83","author":"Jaffin","year":"1987","journal-title":"Am J Med"},{"key":"10.1378\/chest.08-0670_bib353","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0002-9343(88)90105-2","article-title":"Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy","volume":"84","author":"Wilcox","year":"1988","journal-title":"Am J Med"},{"key":"10.1378\/chest.08-0670_bib354","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archinte.1994.00420060075008","article-title":"The significance of hematuria in the anticoagulated patient","volume":"154","author":"Culclasure","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib355","first-page":"791A","article-title":"Incidence and etiology of hematuria in patients on anticoagulant therapy [abstract]","volume":"37","author":"Caralis","year":"1989","journal-title":"Clin Res"},{"key":"10.1378\/chest.08-0670_bib356","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0022-5347(17)44295-9","article-title":"Clinical significance of hematuria in patients on anticoagulant therapy","volume":"137","author":"Schuster","year":"1987","journal-title":"J Urol"},{"key":"10.1378\/chest.08-0670_bib357","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0022-5347(01)67469-X","article-title":"Anticoagulant associated hematuria: a prospective study","volume":"153","author":"Van Savage","year":"1995","journal-title":"J Urol"},{"issue":"119(suppl)","key":"10.1378\/chest.08-0670_bib358","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","article-title":"Oral anticoagulants: mechanism of action, clinical effectiveness, and optimum therapeutic range","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.08-0670_bib359","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0149-2918(04)90187-7","article-title":"Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting","volume":"26","author":"Willey","year":"2004","journal-title":"Clin Ther"},{"key":"10.1378\/chest.08-0670_bib360","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2141.2004.05348.x","article-title":"Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome; a retrospective study of 2300 consecutive patients with venous thromboembolism","volume":"128","author":"Veeger","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.08-0670_bib361","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/archinte.158.15.1641","article-title":"Comparison of an anticoagulation clinic and usual medical care: anticoagulation control, patient outcomes, and health care costs","volume":"158","author":"Chiquette","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib362","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1378\/chest.127.5.1515","article-title":"Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy","volume":"127","author":"Witt","year":"2005","journal-title":"Chest"},{"key":"10.1378\/chest.08-0670_bib363","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1378\/chest.129.5.1155","article-title":"Effect of study setting on anticoagulation control: a systematic review and meta-regression","volume":"129","author":"Van Walraven","year":"2006","journal-title":"Chest"},{"key":"10.1378\/chest.08-0670_bib364","series-title":"Managing oral anticoagulation therapy: clinical and operational guidelines","first-page":"28","article-title":"Capillary whole blood prothrombin time monitoring: instrumentation and methodologies","author":"Ansell","year":"1997"},{"key":"10.1378\/chest.08-0670_bib365","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ajcp\/88.4.442","article-title":"A novel whole blood capillary technique for measuring prothrombin time","volume":"88","author":"Lucas","year":"1987","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib366","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0049-3848(92)90312-X","article-title":"Bedside monitoring of warfarin therapy by a whole blood capillary coagulation monitor","volume":"66","author":"Yano","year":"1992","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0670_bib367","first-page":"864","article-title":"Evaluation of a capillary whole-blood prothrombin time measurement system","volume":"8","author":"Weibert","year":"1989","journal-title":"Clin Pharm"},{"key":"10.1378\/chest.08-0670_bib368","first-page":"611","article-title":"Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer","volume":"117","author":"Rose","year":"1993","journal-title":"Arch Pathol Lab Med"},{"issue":"86(suppl)","key":"10.1378\/chest.08-0670_bib369","first-page":"869a","article-title":"Pilot study to determine use of a TAS analyzer in an anticoagulation clinic setting [abstract]","author":"Fabbrini","year":"1995","journal-title":"Blood"},{"issue":"92(suppl)","key":"10.1378\/chest.08-0670_bib370","first-page":"112b","article-title":"Performance of the AvocetPT prothrombin time system [abstract]","author":"Ansell","year":"1998","journal-title":"Blood"},{"key":"10.1378\/chest.08-0670_bib371","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1055\/s-0037-1613895","article-title":"A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods","volume":"83","author":"Gosselin","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib372","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1055\/s-0037-1614036","article-title":"A comparison of INRs determined with a whole blood prothrombin time device and two international reference preparations for thromboplastin","volume":"84","author":"Van Den Besselar","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib373","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jcp.50.11.951","article-title":"Monitoring oral anticoagulant treatment with the TAS near patient test system: comparison with conventional thromboplastins","volume":"50","author":"Kitchen","year":"1997","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib374","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0049-3848(98)00098-X","article-title":"Accuracy of a portable international normalization ratio monitor in outpatients receiving long-term oral anticoagulant therapy: comparison with a laboratory reference standard using clinically relevant criteria for agreement","volume":"92","author":"Douketis","year":"1998","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0670_bib375","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0049-3848(00)00323-6","article-title":"Accuracy of a portable prothrombin time monitor (CoaguChek) in patients on chronic oral anticoagulant therapy: a prospective multicenter study","volume":"100","author":"Cosmi","year":"2000","journal-title":"Thromb Res"},{"key":"10.1378\/chest.08-0670_bib376","first-page":"109","article-title":"Accuracy and precision of the LifeScan INR monitor in anticoagulation clinics","volume":"12","author":"Earp","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib377","first-page":"280","volume":"115","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib378","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1309\/KM0J-G5V9-KCAG-CLEE","volume":"115","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib379","first-page":"109","article-title":"Patient self-testing with the LifeScan INR monitor [abstract]","volume":"12","author":"Earp","year":"2001","journal-title":"J Thromb Thrombolysis"},{"issue":"86(suppl)","key":"10.1378\/chest.08-0670_bib380","first-page":"863a","article-title":"Monitoring of oral anticoagulant therapy in pediatric patients using a new microsample PT device [abstract]","author":"Andrew","year":"1995","journal-title":"Blood"},{"key":"10.1378\/chest.08-0670_bib381","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/jcp.51.1.68","article-title":"Accuracy and precision of the TAS analyser for near-patient INR testing by non-pathology staff in the community","volume":"51","author":"Cachia","year":"1998","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib382","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/bmj.327.7405.5","article-title":"INRs and point of care testing","volume":"327","author":"Murray","year":"2003","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0670_bib383","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/jcp.44.11.950","article-title":"Evaluation of the Ciba-Corning Biotrack 512 coagulation monitor for the control of oral anticoagulation","volume":"44","author":"Jennings","year":"1991","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib384","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archinte.1992.00400150103019","article-title":"Accuracy and precision of a portable anticoagulation monitor in a clinical setting","volume":"152","author":"McCurdy","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib385","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1055\/s-0038-1649700","article-title":"Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the international normalized ratio?","volume":"70","author":"Tripodi","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib386","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1055\/s-0038-1657641","article-title":"Determination of the international sensitivity index of a new near-patient testing device to monitor oral anticoagulant therapy","volume":"78","author":"Tripodi","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib387","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1160\/TH05-06-0400","article-title":"Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies","volume":"94","author":"Perry","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib388","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/archinte.1995.00430170053006","article-title":"Accuracy of laboratory and portable monitor international normalized ratio determinations","volume":"155","author":"Kaatz","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib389","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1046\/j.0007-1048.2002.03361.x","article-title":"European concerted action on anticoagulation: multicentre international sensitivity index calibration of two types of point-of-care prothrombin time monitor systems","volume":"116","author":"Poller","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.08-0670_bib390","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/jcp.56.2.114","article-title":"An assessment of lyophilised plasmas for ISI calibration of CoaguChek and TAS whole blood prothrombin time monitors","volume":"56","author":"Poller","year":"2003","journal-title":"J Clin Pathol"},{"key":"10.1378\/chest.08-0670_bib391","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/bmj.327.7405.30","article-title":"Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods","volume":"327","author":"Poller","year":"2003","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0670_bib392","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1160\/TH04-01-0031","article-title":"Point-of-care International Normalised Ratios: UK NEQAS experience demonstrates necessity for proficiency testing of three different monitors","volume":"96","author":"Kitchen","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib393","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0002-8703(96)90040-X","article-title":"Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring and patient self-management","volume":"132","author":"Ansell","year":"1996","journal-title":"Am Heart J"},{"key":"10.1378\/chest.08-0670_bib394","first-page":"454","article-title":"A self control method for long term anticoagulation therapy","volume":"15","author":"Erdman","year":"1974","journal-title":"J Cardiovasc Surg"},{"key":"10.1378\/chest.08-0670_bib395","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11239-004-0209-5","article-title":"Self-management of oral anticoagulant therapy: a review","volume":"18","author":"Christensen","year":"2004","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib396","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1160\/TH03-09-0598","article-title":"A systematic review of studies of self-management of oral anticoagulation","volume":"91","author":"Siebenhofer","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib397","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0140-6736(06)68139-7","article-title":"Self-monitoring of oral anticoagulation: a systematic review and meta-analysis","volume":"367","author":"Heneghan","year":"2006","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib398","doi-asserted-by":"crossref","first-page":"730","DOI":"10.7326\/0003-4819-111-9-730","article-title":"Home prothrombin time monitoring after the initiation of warfarin therapy: a randomized, prospective study","volume":"111","author":"White","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.08-0670_bib399","first-page":"111","article-title":"Anticoagulation therapy home and office monitoring evaluation study","volume":"12","author":"Kaatz","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib400","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0003-4975(01)03049-1","article-title":"Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients","volume":"72","author":"Sidhu","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"10.1378\/chest.08-0670_bib401","first-page":"1117","article-title":"A randomized trial of patient self-managed versus physician-managed oral anticoagulation","volume":"20","author":"Sunderji","year":"2004","journal-title":"Can J Cardiol"},{"key":"10.1378\/chest.08-0670_bib402","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00392-005-0199-0","article-title":"Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study)","volume":"94","author":"Voller","year":"2005","journal-title":"Z Kardiol"},{"key":"10.1378\/chest.08-0670_bib403","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2141.2004.05074.x","article-title":"The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation","volume":"126","author":"Khan","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1378\/chest.08-0670_bib404","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11239-005-1452-0","article-title":"The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study 481; the Home INR Study (THINRS)","volume":"19","author":"Matchar","year":"2005","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib405","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijcard.2003.11.008","article-title":"Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation","volume":"99","author":"Ansell","year":"2004","journal-title":"Int J Cardiol"},{"key":"10.1378\/chest.08-0670_bib406","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2141.2005.05739.x","article-title":"An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation","volume":"131","author":"Fitzmaurice","year":"2005","journal-title":"Br J Haematol"},{"issue":"suppl","key":"10.1378\/chest.08-0670_bib407","doi-asserted-by":"crossref","first-page":"Q65","DOI":"10.1016\/S1520-765X(01)90046-X","article-title":"Economic analysis of bleeding and thromboembolic sequelae after heart valve replacement (GELIA 7): the GELIA Study Group","volume":"3","author":"Muller","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.08-0670_bib408","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1538-7836.2004.00659.x","article-title":"Patient self-management of oral anticoagulant care vs management by specialized anticoagulation clinics: positive effects on quality of life","volume":"2","author":"Gadisseur","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1378\/chest.08-0670_bib409","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1503\/cmaj.051104","article-title":"Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy","volume":"174","author":"Regier","year":"2006","journal-title":"Can Med Assoc J"},{"issue":"5(suppl)","key":"10.1378\/chest.08-0670_bib410","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1023\/A:1013276601930","article-title":"Anticoagulation management as a risk factor for adverse events: grounds for improvement","author":"Ansell","year":"1998","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib411","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/archinte.160.7.967","article-title":"Quality of anticoagulation management among patients with atrial fibrillation: results from a review of medical records from two communities","volume":"160","author":"Samsa","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1378\/chest.08-0670_bib412","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bmj.289.6442.422","article-title":"Computer assisted management of warfarin treatment","volume":"289","author":"Wilson","year":"1984","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0670_bib413","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/bmj.299.6709.1207","article-title":"Computer control of anticoagulant dose for therapeutic management","volume":"299","author":"Ryan","year":"1989","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0670_bib414","first-page":"1529","article-title":"Computer control of anticoagulant dose [letter]","volume":"299","author":"Weston Smith","year":"1989","journal-title":"BMJ"},{"key":"10.1378\/chest.08-0670_bib415","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/jcp.46.4.299","article-title":"Prospective comparative study of computer programs used for management of warfarin","volume":"46","author":"Poller","year":"1993","journal-title":"J Clin Pathol"},{"issue":"5(suppl)","key":"10.1378\/chest.08-0670_bib416","first-page":"S69","article-title":"A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy [abstract]","author":"Ageno","year":"1998","journal-title":"J Thromb Thrombolysis"},{"key":"10.1378\/chest.08-0670_bib417","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(98)04147-6","article-title":"The European Concerted Action on Anticoagulation (ECAA): multicentre randomized study of computerized anticoagulant dosage","volume":"352","author":"Poller","year":"1998","journal-title":"Lancet"},{"key":"10.1378\/chest.08-0670_bib418","first-page":"1060","article-title":"Effect of computer aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT","volume":"86","author":"Manotti","year":"2001","journal-title":"Haematologica"},{"key":"10.1378\/chest.08-0670_bib419","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1055\/s-0037-1613932","article-title":"A computer generated induction system for hospitalized patients starting on oral anticoagulant therapy","volume":"83","author":"Ageno","year":"2000","journal-title":"Thromb Haemost"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369208601178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369208601178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T15:06:39Z","timestamp":1709046399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369208601178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":419,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0012369208601178"],"URL":"https:\/\/doi.org\/10.1378\/chest.08-0670","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}